Discussing the recent Phase 3 TROPiCS-02 data on Trodelvy in HR+/HER2- metastatic breast cancer presented at ESMO 2022

Executed on:Sep 22, 2022 10:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Cancer Center of Kansas

President of CCoK, Clinical Professor of Medicine at University of Kansas, and Founder of the Wichita Cancer Foundation
Board certified in Medical Oncology and Hematology and treats more than 75 patients with HR+/HER2 metastatic breast cancer
Involved in oncology research at a local and national level being the Principal Investigator of the Wichita NCI Community Oncology Research Program

Interview Goal

This conversation will focus on the  potential of Gilead's Trodelvy(sacituzumab govitecan) in HR+/HER2- metastatic breast cancer. We will dig into the P3 overall survival data presented at ESMO with a breast cancer KOL.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.